Polyclonal antibody to zeb1 hpa027524

Manufactured by Merck Group

Sourced in United States

Polyclonal antibody to ZEB1 (HPA027524) is a laboratory product manufactured by Merck Group. It is a reagent used in research applications. The core function of this product is to specifically bind and detect the ZEB1 protein, which is a transcription factor involved in various biological processes. This antibody can be utilized in techniques such as immunohistochemistry, immunocytochemistry, and Western blotting to study the expression and localization of the ZEB1 protein in various samples.

Automatically generated - may contain errors

Lab products found in correlation

P p38 9211s, by Cell Signaling Technology (1 mentions) Sox2 sc17319, by Santa Cruz Biotechnology (1 mentions) Monoclonal antibodies to β actin, by Merck Group (1 mentions) Twist sc 15393, by Santa Cruz Biotechnology (1 mentions) 4 6 diamidino 2 phenylindole (dapi), by Merck Group (1 mentions) N cadherin 610920, by BD (1 mentions)

2 protocols using polyclonal antibody to zeb1 hpa027524

Antibody Sources and Reagents for EMT Study

Check if the same lab product or an alternative is used in the 5 most similar protocols

Polyclonal antibody to CD44 (ab41478) was obtained from Abcam (Seoul, Korea). Polyclonal antibodies to AKT (9272S), p-AKT (S473) (9271S), p-AKT (T308) (9275S), SNAIL (3879), P38 (9121), and p-p38 (9211S) were obtained from Cell Signaling Technology (Beverly, MA, USA). Polyclonal antibodies to vimentin (sc-5565), SLUG (SC-10436), TWIST (sc-15393), c-SRC (sc-19), Lyn (sc-15), Fyn (sc-16), LCK (sc-13), and SOX2 (sc17319) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Polyclonal antibody to ZEB1 (HPA027524) was purchased from Sigma (St. Louis, MO, USA). Polyclonal antibodies to N-cadherin (610920) and E-cadherin (612130) were purchased from BD Transduction Laboratory (Seoul, Korea). Monoclonal antibodies to β-actin and DAPI were purchased from Sigma. Etoposide (341205), cisplatin (232120), and LY294002 a chemical inhibitor specific to PI3K (440202), were purchased from Calbiochem (San Diego, CA, USA). Paclitaxel (T1912-5MG) was purchased from Sigma.

Kim R.K., Cui Y.H., Yoo K.C., Kim I.G., Lee M., Choi Y.H., Suh Y, & Lee S.J. (2014). Radiation promotes malignant phenotypes through SRC in breast cancer cells. Cancer Science, 106(1), 78-85.

+ Open protocol

+ Expand

Exploring Epithelial-Mesenchymal Transition Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Monoclonal antibodies to N-cadherin (610920) and E-cadherin (612130) were purchased from BD Transduction Laboratory (Seoul, Korea). Polyclonal antibodies to STAT3 (sc-482), NF-κB (p65) (sc- 109), Vimentin (sc-5565), SLUG (sc-10436) and TWIST (sc- 15393) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The polyclonal antibody to ZEB1 (HPA027524) was purchased from Sigma (St Louis, MO, USA). The polyclonal antibodies to Snail (3879), p-STAT3 (Y705) (9131), p-STAT3 (S727) (9134), Fra1 (5281), p-Fra1 (3880) and Notch1 (2421) were obtained from Cell Signaling Technology (Beverly, MA, USA). Polyclonal antibodies to anti-IL-6 (ab6672), Notch2 (ab72803), Jagged1 (ab109536) and DLL4 (ab7280) were purchased from Abcam (Cambridge, UK. Monoclonal antibody to β-actin and 4, 6-diamidino-2-phenylindole (DAPI) were purchased from Sigma (St Louis, MO, USA). The chemical inhibitors including Gamma secretase inhibitor (565770), STAT3 inhibitor (573097) and the JAK inhibitor (420099) were bought from Calbiochem (San Diego, CA, USA). Recombinant human CXCL8/IL-8 protein was purchased from R & D systems and recombinant protein IL-6 was bought from EMD Millipore.

Kim R.K., Kaushik N., Suh Y., Yoo K.C., Cui Y.H., Kim M.J., Lee H.J., Kim I.G, & Lee S.J. (2016). Radiation driven epithelial-mesenchymal transition is mediated by Notch signaling in breast cancer. Oncotarget, 7(33), 53430-53442.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!